CAS: 136949-58-1; Iobitridol

该化合物是一种在放射成像程序(包括计算断层和血管成像)中常用的非离子,低烟雾的碘化对照介质,其分子结构以三亚苯环为特征,并配有水利链条,确保水溶性高,减少浮游性,尽量减少不良反应的风险.Iobitridol 表现出了极好的可耐性,由于化学毒性低,血液动力稳定性稳定,具有有利的安全性.它提供了高辐射密度,使血管和近距离结构能够清晰地视觉化.该化合物迅速排出,减少了系统性接触.它的平衡性和碘浓度使得它适合广泛的诊断应用,同时保持病人的舒适.

结构式图片

MSDS等安全信息

    上下游产品

    dimethyl 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylate 2,4,6-triiodo-5-aminoisophthalic acid

    合成工艺路线路线简述

      Dimethyl 5-Amino-2,4,6-Triiodo-1,3-Benzenedicarboxylate置于n,N-二甲基乙酰胺,三光气,三乙胺,Lithium Hydroxide体系中,用 四氢呋喃,乙醇,二氯甲烷,水 用作溶剂,化学反应 81.5H,反应生成碘比醇
      参考文献:制备碘比醇的方法,其中间体及其制备方法
      标题:制备碘比醇的方法,其中间体及其制备方法
      摘要:本发明公开了制备碘比醇的方法,其中间体及其制备方法.具体公开了一种用于制备碘比醇的中间体m1 5‑(2‑异丙基‑1,3‑二氧己环‑5‑羰酰基)‑2,4,6‑三碘间苯二甲酸.此外,本发明还公开了所述中间体m1的制备方法以及由该中间体制备碘比醇的方法.本发明的中间体活性高,易制备,由该中间体合成碘比醇的方法时间短,合成方法简单,综合成本低,且反应目标物的收率和纯度高,因此适用于工业化生产.

      海关参考信息

      专利信息


      专利号:US-2022233673-A1
      优先权日:2019-06-04
      标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
      发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
      权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
      摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

      专利号:US-10836711-B2
      优先权日:2017-02-10
      标 题 :Method for the one-pot production of organo-iodinated compounds
      发明人:PETTA MYRIAM; PELLINGHELLI STEPHAN
      权利人:GUERBET SA
      摘要:The present invention concerns a process for the preparation of organo-iodized compounds, as well as their preparation intermediates. More particularly, the present invention concerns a process for the preparation of organo-iodized compounds which can be used as preparation intermediates in the synthesis of iodized contrast agents.

      专利号:US-11472767-B2
      优先权日:2018-08-02
      标 题 :Process for the monotopic preparation of intermediate organo-iodinated compounds for the synthesis of ioversol
      发明人:STÉPHAN PELLINGHELLI; PETTA MYRIAM
      权利人:GUERBET SA
      摘要:A process for preparing an organo-iodinated compound, comprising the following steps:a) acylating 2,4,6-triiodo-5-aminoisophthalic acid of formula (A) below:to obtain an intermediate compound Ya;b) chlorinating the intermediate compound Ya to obtain an organo-iodinated intermediate compound Yb;c) amidating the organo-iodinated intermediate compound Yb to obtain an intermediate compound Yc; andd) deprotecting the intermediate compound Yc, the steps a), b), c) and d) being carried out without isolation of at least one intermediate compound chosen from Ya and Yc.

      专利号:US-10836710-B2
      优先权日:2016-12-05
      标 题 :Mechanochemical synthesis of radiographic agents intermediates
      发明人:BARGE ALESSANDRO; BARICCO FRANCESCA; CRAVOTTO GIANCARLO; FRETTA ROBERTA; LATTUADA LUCIANO
      权利人:BRACCO IMAGING SPA
      摘要:The present invention generally relates to a process using a mechanochemical approach exploiting the mechanical milling of reactants for the manufacturing of acetyl Iopamidol and, more generally, of key intermediates of radiographic contrast agents, and of the contrast agents themselves.

      专利号:US-2022118123-A1
      优先权日:2019-02-22
      标 题 :Combination of ar antagonists and targeted thorium conjugates
      发明人:HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
      权利人:BAYER AG; BAYER AS
      摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

      专利号:US-2011104052-A1
      优先权日:2007-12-03
      标 题 :Methods of synthesis and use of chemospheres
      发明人:BARNETT BRADLEY POWERS; GESCHWIND JEFFREY
      权利人:UNIV JOHNS HOPKINS
      摘要:The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.
      江苏宇田医药股份有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.jsytsw.com
      企业联系电话:0518-86098000;86098017👤
      📞江苏宇田医药股份有限公司 ⚠️参考联系方式
      联系人:王先生;樊女士
      电话:0518-86098000;86098017
      手机:15261372765;18861350683

      邮箱:sales@jsytsw.com
      通信地址: 江苏连云港市经济技术开发区大浦工业区临浦路22号
      邮编: 222000
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      地址:江苏连云港市经济技术开发区大浦工业区临浦路22号
      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
      ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Kim YS, Yoon SH, Choi YH, Park CM, Lee W, Goo JM. Nausea and vomiting after exposure to non-ionic contrast media: incidence and risk factors focusing on preparatory fasting. Br J Radiol. 2018 Apr
      25:20180107. doi: 10.1259/bjr.20180107. [Epub ahead of print] pii: 1703261. doi: 10.1002/adfm.201703261. Epub 2017 Aug 21.
      3: Piacentino F, Fontana F, Micieli C, Angeretti MG, Cardim LN, Coppola A, Molinelli V, Piffaretti G, Novario R, Fugazzola C. Nonenhanced MRI Planning for Endovascular Repair of Abdominal Aortic Aneurysms: Comparison With Contrast-Enhanced CT Angiography. Vasc Endovascular Surg. 2018 Jan;52(1):39-45. doi: 10.1177/1538574417740508. Epub 2017 Nov 21. doi: 10.1177/0284185117726101. Epub 2017 Aug 8. doi: 10.1016/j.ejrad.2017.05.017. Epub 2017 May 17. doi: 10.1007/s00330-016-4682-y. Epub 2016 Dec 14. doi: 10.1111/cea.12803. Epub 2016 Oct 12. Erratum to: Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Eur Radiol. 2017 Feb;27(2):831. doi: 10.1007/s00330-016-4557-2. Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Eur Radiol. 2017 Feb;27(2):821-830. doi: 10.1007/s00330-016-4437-9. Epub 2016 Jun 7. Erratum in: Eur Radiol. 2017 Feb;27(2):831.

      合成参考文献


      摘要:Acta Radiologica, Supplementum., 400(17), 1996 []
      摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from
      参考文献:10.1007/s00261-003-0063-5
      摘要:Catry F, Geusens E, Vanbeckevoort D, Volders W, Bielen D, Spitz B. Delivery related rupture of the gravid uterus: imaging findings: a case report. Abdominal Radiology. 2003 Oct 28;29(1):120–2. doi: 10.1007/s00261-003-0063-5.
      参考文献:10.1097/maj.0b013e3181c06e70
      摘要:Alexopoulos E, Spargias K, Kyrzopoulos S, Manginas A, Pavlides G, Voudris V, Cokkinos DV, Lerakis S, Mclean DS. Contrast-Induced Acute Kidney Injury in Patients With Renal Dysfunction Undergoing a Coronary Procedure and Receiving Non-Ionic Low-Osmolar Versus Iso-Osmolar Contrast Media. The American Journal of the Medical Sciences. 2010 Jan;339(1):25–30. doi: 10.1097/maj.0b013e3181c06e70.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知